title: Kidney cancer: current and novel treatment options.
abstract: Antiangiogenic therapies remain the standard of care in the front-line setting for renal cell carcinoma, although vascular endothelial growth factor (VEGF) blockade is not sufficient, and many patients do not respond to such treatment. With a host of approved agents, questions arise as to how best to use them in both initial and secondary treatments. Optimal sequences are currently being tested in various clinical trials. Because approximately 20% of patients exhibiting primary resistance to these anti-VEGF therapies, new therapies are needed. Novel therapies such as MET and AXL inhibitors as well as checkpoint antibodies hold promise for the future.
authors.affiliation: Presented by Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel-Lindau Clinical Center at The University of Texas MD Anderson Cancer Center and co-Director of the MD Anderson Kidney Cancer Research Program, Houston, Texas.
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017410:Practice Guidelines as Topic; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A